Transcatheter aortic valve implantation in rheumatic aortic stenosis

Paul T.L. Chiam
AsiaIntervention 2018;4:11-13 DOI: 10.4244/AIJV4I1A3

Transcatheter aortic valve implantation (TAVI) has become an established treatment for patients with severe aortic valve stenosis (AS) who are inoperable or at high surgical risk, and an attractive alternative in intermediate surgical-risk patients. Two years after TAVI achieved European commercial approval (CE mark), the technology became established in Asia. As with the global experience, TAVI has been increasingly applied in Asia to off-label indications such as bicuspid AS, degenerated surgical bioprosthesis (valve-in-valve TAVI), non-calcific AS, and pure aortic regurgitation.

To download, please click below.